Neose Announces Two Abstracts on GlycoPEGylated Factor VIIa Accepted for Presentation at the Hemophilia 2008 World Congress
The presentations are as follows:
-- Oral Presentation entitled "Prolonged Duration of Effect of GlycoPEGylated rFVIIa in a Venous Stasis Model" to be presented on Wednesday, June 4 between 11:00 a.m. and 12:30 p.m. EEST in Dolmabahce A
-- Poster Presentation entitled "The Haemostatic Activity of GlycoPEGylated Variants of rFVIIa Studied in vitro Under Static and Flow Conditions in Human Blood" to be presented Monday, June 2 and Tuesday, June 3 between 9:00 a.m. and 5:15 p.m. EEST in Rumeli Hall
About Coagulation Factor VIIa
Recombinant Factor VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VIIa was approximately $1 billion in 2006, with Novo Nordisk being the only participant.
About Novo Nordisk A/S
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.
About Neose Technologies, Inc.
Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market. The lead candidates in its pipeline, GlycoPEG-GCSF for chemotherapy-induced neutropenia, and the GlycoPEGylated hemostasis compounds Factor VIIa, Factor VIII, and Factor IX, target markets with aggregate 2006 sales of approximately $8 billion. For more information, please visit www.neose.com.
Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the sections of Neose's Annual Report on Form 10-K for the year ended December 31, 2007, entitled "Risk Factors" and "Special Note Regarding Forward-Looking Statements" and discussions of potential risks and uncertainties in Neose's subsequent filings with the SEC.
Contact
Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
215-315-9000
Posted: May 2008
